Uppsala, Sweden, 29 January 2010
Beactica AB, the leading Swedish fragment-based drug discovery company, today announced a new investment and the addition of Innovationsbron AB to its shareholders. They join Uppsala University Holding Company and the founders as continuing investors. The funds will be used to finance the progression of Beactica’s internal drug discovery pipeline.
“We are delighted to welcome Innovationsbron as a shareholder” said Beactica CEO, Dr Per Källblad. “Innovationsbron has a strong track record in the commercialization of research concepts and their wide expertise will provide a valuable contribution as we move forward”.
VP Regional Director Mid-Sweden at Innovationsbron, Tomas Nygren, said “From day one Beactica has successfully delivered high-value services to a growing number of global life-science companies. Supporting Beactica in enhancing their drug discovery operations perfectly matches our mission to turn excellent research and innovation into business.”
For additional information, please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80, or Tomas Nygren, VP Regional Director Mid-Sweden at Innovationsbron AB, +46 18 51 05 99.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. Beactica’s Sprint™ drug discovery platform efficiently integrates SPR biosensor-based interaction analysis and drug design to accelerate the identification of optimal starting points and development routes for lead discovery. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit www.beactica.com.
Innovationsbron AB is a Swedish company established in the spring of 2005 with seven offices in Luleå, Umeå, Uppsala, Stockholm, Linköping, Göteborg and Lund. Innovationsbron specializes in the commercialization of excellent research and innovation in Sweden and provides business development, a national incubation programme and seed capital. Innovationsbron has at its disposal approximately SEK 2 billion in capital for ten years. It is owned by the Swedish state and Industrifonden. For more information about Innovationsbron, please visit www.innovationsbron.se.